Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fengting Yu, Qun Li, Linghang Wang, Hongxin Zhao, Hao Wu, Siyuan Yang, Yunxia Tang, Jiang Xiao & Fujie Zhang. (2022) Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China. Pharmacogenomics and Personalized Medicine 15, pages 195-203.
Read now
Read now
Elisabeth Olliges, Bernhard Bührlen, Franz Fischer, Christoph Boesecke, Tim Kümmerle, Jochen Schneider, Simon Weidlich, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Erik-Ole Jensen, Eva Wolf, Joram Ronel, Christoph D. Spinner & on behalf of the DUALIS STUDY GROUP. (2022) Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study. AIDS Care 34:6, pages 698-707.
Read now
Read now
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti & Simona Di Giambenedetto. (2020) Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy 18:4, pages 279-292.
Read now
Read now
Vincenzo Spagnuolo, Caterina Uberti-Foppa & Antonella Castagna. (2019) Pharmacotherapeutic management of HIV in transplant patients. Expert Opinion on Pharmacotherapy 20:10, pages 1235-1250.
Read now
Read now
Articles from other publishers (45)
Alicja Jakimiuk, Agnieszka Piechal, Alicja Wiercińska-Drapało, Alicja Nowaczyk & Dagmara Mirowska-Guzel. (2023) Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies. Pharmacological Reports.
Crossref
Crossref
Eric Wei Chiang Chan, Mio Kezuka, Hung Tuck Chan & Siu Kuin Wong. (2023) <i>Alpinia zerumbet</i>: A Review of the Chemistry, Quantity, and Pharmacological Properties of Selected Kavalactones. Journal of Natural Remedies, pages 699-709.
Crossref
Crossref
Sha Hu, Jiong Chen, Jin-Xu Cao, Shuang-Shuang Zhang, Shuang-Xi Gu & Fen-Er Chen. (2023) Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities. Bioorganic Chemistry 136, pages 106549.
Crossref
Crossref
Daniele Armenia, Maria M Santoro, Charlotte Charpentier, Ada Bertoli, Federica Forbici, Vincent Calvez, Diane Descamps, Francesca Ceccherini-Silberstein, Anne-Genevieve Marcelin & Philippe Flandre. (2023) Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. Journal of Antimicrobial Chemotherapy 78:6, pages 1415-1422.
Crossref
Crossref
Edgar Pérez-Barragán, Mónica Fernanda Guevara-Maldonado, Javier Mancilla-Galindo, Ashuin Kammar-García, Alejandro Ortiz-Hernández, José Antonio Mata-Marín & Samantha Pérez-Cavazos. (2023) Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients. AIDS Research and Human Retroviruses.
Crossref
Crossref
Bruce Nzimande, John P. Makhwitine, Nompumelelo P. Mkhwanazi & Sizwe I. Ndlovu. (2023) Developments in Exploring Fungal Secondary Metabolites as Antiviral Compounds and Advances in HIV-1 Inhibitor Screening Assays. Viruses 15:5, pages 1039.
Crossref
Crossref
Sharif Karim Sayyed, Marzuqa Quraishi, Renitta Jobby, Neelamegam Rameshkumar, Nagarajan Kayalvizhi, Muthukalingan Krishnan & Tareeka Sonawane. (2023) A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants. Archives of Microbiology 205:4.
Crossref
Crossref
Anjali Jayasree Balakrishnan, Aswathi Kodenchery Somasundaran, Prajit Janardhanan & Rajendra Pilankatta. 2023. Antimicrobial Peptides. Antimicrobial Peptides
219
235
.
Chia‐Ching J. Wang & Elizabeth Y. Chiao. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
18
.
Talal El Zarif, Marcel Yibirin, Diana De Oliveira-Gomes, Marc Machaalani, Rashad Nawfal, Gianfranco Bittar, Hisham F. Bahmad & Nizar Bitar. (2022) Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing. Cancers 14:9, pages 2105.
Crossref
Crossref
Ahmed Badat & Karishma Lowton. (2022) Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen. South African Journal of Psychiatry 28.
Crossref
Crossref
Shiridhar Kashyap, Maryam Rabbani, Isabela de Lima, Olena Kondrachuk, Raj Patel, Mahnoush Sophia Shafiei, Avni Mukker, Aishwarya Rajakumar & Manish Kumar Gupta. (2021) HOPX Plays a Critical Role in Antiretroviral Drugs Induced Epigenetic Modification and Cardiac Hypertrophy. Cells 10:12, pages 3458.
Crossref
Crossref
Li Wei Ang, Oon Tek Ng, Irving Charles Boudville, Yee Sin Leo & Chen Seong Wong. (2021) An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore. PLOS ONE 16:6, pages e0252320.
Crossref
Crossref
Harsha Kharkwal, Banoth K Kumar, Sankaranarayanan Murugesan, Gautam Singhvi, Preeti Avasthi, Ankush Goyal, Joazaizulfazli Jamalis & Subhash Chander. (2021) Search for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challenges. Future Medicinal Chemistry 13:3, pages 269-286.
Crossref
Crossref
Young Hyun Shin, Chul Min Park & Cheol-Hee Yoon. (2021) An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status. Infection & Chemotherapy 53:1, pages 29.
Crossref
Crossref
Arturo CicculloGianmaria BaldinVanni BorghiGaetana SterrantinoGiordano MadedduAlessandra LatiniGabriella d'EttorreAlessandro LanariMaria MazzitelliManuela ColafigliAmedeo Ferdinando CapettiLetizia OreniFilippo LagiStefano RusconiSimona Di Giambenedetto. (2021) Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. AIDS Research and Human Retroviruses 37:1, pages 4-10.
Crossref
Crossref
Yang Li, Yujia Tian, Yao Xi, Zijian Qin & Aixia Yan. (2020) Quantitative Structure-Activity Relationship Study for HIV-1 LEDGF/p75 Inhibitors. Current Computer-Aided Drug Design 16:5, pages 654-666.
Crossref
Crossref
Daniele Armenia, Yagai Bouba, Roberta Gagliardini, Caterina Gori, Ada Bertoli, Vanni Borghi, William Gennari, Valeria Micheli, Anna Paola Callegaro, Lidia Gazzola, Bianca Bruzzone, Alberto Giannetti, Valentina Mazzotta, Alessandra Vergori, Ilaria Mastrorosa, Manuela Colafigli, Miriam Lichtner, Antonio di Biagio, Franco Maggiolo, Giuliano Rizzardini, Antonella d’Arminio Monforte, Massimo Andreoni, Cristina Mussini, Andrea Antinori, Francesca Ceccherini-Silberstein, Carlo Federico Perno & Maria Mercedes Santoro. (2020) Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Journal of Clinical Virology 130, pages 104534.
Crossref
Crossref
Ramandeep Kaur, Pooja Sharma, Girish K. Gupta, Fidele Ntie-Kang & Dinesh Kumar. (2020) Structure-Activity-Relationship and Mechanistic Insights for Anti-HIV Natural Products. Molecules 25:9, pages 2070.
Crossref
Crossref
Hannes Lengauer, Damjan Makuc, Damjan Šterk, Franc Perdih, Arthur Pichler, Tina Trdan Lušin, Janez Plavec & Zdenko Časar. (2020) Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates. Pharmaceutics 12:4, pages 342.
Crossref
Crossref
Lifeng Liu, Lili Dai, Jun Yao, Pinliang Pan, Li Li, Zhiying Liu, Xizhao An, Lijun Sun, Hao Wu, Bin Su & Tong Zhang. (2019) Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China. AIDS 33:12, pages 1945-1947.
Crossref
Crossref
Laurent Chouchana, Nathanael Beeker & Jean-Marc Treluyer. (2019) Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?. JAIDS Journal of Acquired Immune Deficiency Syndromes 81:4, pages 481-486.
Crossref
Crossref
Orlanda Q Goh, Donn J Colby, Suteeraporn Pinyakorn, Carlo Sacdalan, Eugène Kroon, Phillip Chan, Nitiya Chomchey, Ratchapong Kanaprach, Peeriya Prueksakaew, Duanghathai Suttichom, Rapee Trichavaroj, Serena Spudich, Merlin L Robb, Praphan Phanuphak, Nittaya Phanuphak & Jintanat Ananworanich. (2019)
Switch to dolutegravir is well tolerated in Thais with
HIV
infection
. Journal of the International AIDS Society 22:7.
Crossref
Crossref
Lavanya Singh, Hendrik G. Kruger, Glenn E. M. Maguire, Thavendran Govender & Raveen Parboosing. (2018) Development and Evaluation of Peptide-Functionalized Gold Nanoparticles for HIV Integrase Inhibition. International Journal of Peptide Research and Therapeutics 25:1, pages 311-322.
Crossref
Crossref
Ricky Hsu, Jennifer Fusco, Cassidy Henegar, Karam Mounzer, Michael Wohlfeiler, Vani Vannappagari, Michael Aboud, Lloyd Curtis & Gregory Fusco. (2018) Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety 9:12, pages 675-686.
Crossref
Crossref
Eungi Choi, Jayapal Reddy Mallareddy, Dai Lu & Srikanth Kolluru. (2018) Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Science OA 4:9, pages FSO338.
Crossref
Crossref
José L. Blanco, Anne-Geneviéve Marcelin, Christine Katlama & Esteban Martinez. (2018) Dolutegravir resistance mutations. Current Opinion in Infectious Diseases 31:3, pages 237-245.
Crossref
Crossref
Bahare Salehi, Nanjangud Kumar, Bilge Şener, Mehdi Sharifi-Rad, Mehtap Kılıç, Gail Mahady, Sanja Vlaisavljevic, Marcello Iriti, Farzad Kobarfard, William Setzer, Seyed Ayatollahi, Athar Ata & Javad Sharifi-Rad. (2018) Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus. International Journal of Molecular Sciences 19:5, pages 1459.
Crossref
Crossref
James DemarestMark UnderwoodMarty St. ClairDavid DoreyDannae BrownAndrew Zolopa. (2018) Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Research and Human Retroviruses 34:4, pages 343-346.
Crossref
Crossref
Yuqing Gong, Pallabita Chowdhury, Narasimha M. Midde, Mohammad A. Rahman, Murali M. Yallapu & Santosh Kumar. (2017) Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. Biochemistry and Biophysics Reports 12, pages 214-219.
Crossref
Crossref
Elżbieta Jabłonowska, Piotr Pulik, Anna Kalinowska, Jacek Gąsiorowski, Miłosz Parczewski, Monika Bociąga-Jasik, Łukasz Pulik, Ewa Siwak & Kamila Wójcik. (2017) Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. Journal of Medical Virology 89:12, pages 2122-2129.
Crossref
Crossref
A Inciarte, L Leal, E González, A León, C Lucero, J Mallolas, B Torres, M Laguno, J Rojas, M Martínez-Rebollar, A González-Cordón, A Cruceta, J A Arnaiz, J M Gatell, F García, Eva González, Lorna Leal, Agathe León, Berta Torres, Alexy Inciarte, Constanza Lucero, José L Blanco, Esteban Martínez, Josep Mallolas, Josep M Miró, Monserrat Laguno, Jhon Rojas, María Martínez-Rebollar, Ana González-Cordón, Christian Manzardo, Cristina de la Calle, Gerard Espinosa, Joan Albert Arnaiz, Jose M Gatell, Felipe García, Juan Manuel Pericas, David Nicolás, Marta Bodro, Ana del Río & Celia Cardozo. (2017) Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. Journal of Antimicrobial Chemotherapy 72:10, pages 2857-2861.
Crossref
Crossref
Biswajit G Roy. (2017) Potential of small-molecule fungal metabolites in antiviral chemotherapy. Antiviral Chemistry and Chemotherapy 25:2, pages 20-52.
Crossref
Crossref
Thibault Mesplède, Jing Leng, Hanh Thi Pham, Jiaming Liang, Yudong Quan, Yingshan Han & Mark A. Wainberg. (2017) The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. mBio 8:2.
Crossref
Crossref
Anna Fettiplace, Chris Stainsby, Alan Winston, Naomi Givens, Sarah Puccini, Vani Vannappagari, Ricky Hsu, Jennifer Fusco, Romina Quercia, Michael Aboud & Lloyd Curtis. (2017) Psychiatric Symptoms in Patients Receiving Dolutegravir. JAIDS Journal of Acquired Immune Deficiency Syndromes 74:4, pages 423-431.
Crossref
Crossref
Eugenia Negredo, David Back, José-Ramón Blanco, Julià Blanco, Kristine M. Erlandson, Maite Garolera, Giovanni Guaraldi, Patrick Mallon, José Moltó, José Antonio Serra & Bonaventura Clotet. (2017) Aging in HIV-Infected Subjects: A New Scenario and a New View. BioMed Research International 2017, pages 1-9.
Crossref
Crossref
Ying-Shan Han, Thibault Mesplède & Mark A. Wainberg. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
559
564
.
Adam Trickey, Margaret T. May, Janne Vehreschild, Niels Obel, Michael John Gill, Heidi Crane, Christoph Boesecke, Hasina Samji, Sophie Grabar, Charles Cazanave, Matthias Cavassini, Leah Shepherd, Antonella d’Arminio Monforte, Colette Smit, Michael Saag, Fiona Lampe, Vicky Hernando, Marta Montero, Robert Zangerle, Amy C. Justice, Timothy Sterling, Jose Miro, Suzanne Ingle & Jonathan A. C. Sterne. (2016) Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 11:8, pages e0160460.
Crossref
Crossref
Ricardo Moure, Pere Domingo, José M. Gallego-Escuredo, Joan Villarroya, Maria del Mar Gutierrez, Maria G. Mateo, Joan C. Domingo, Marta Giralt & Francesc Villarroya. (2016) Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Research 132, pages 59-65.
Crossref
Crossref
Winston Yan Wang, Jack Ho Wong, Denis Tsz Ming Ip, David Chi Cheong Wan, Randy Chifai Cheung & Tzi Bun Ng. (2016) Bovine Lactoferrampin, Human Lactoferricin, and Lactoferrin 1-11 Inhibit Nuclear Translocation of HIV Integrase. Applied Biochemistry and Biotechnology 179:7, pages 1202-1212.
Crossref
Crossref
Emilie Elliot, Alieu Amara, Akil Jackson, Graeme Moyle, Laura Else, Saye Khoo, David Back, Andrew Owen & Marta Boffito. (2016) Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. Journal of Antimicrobial Chemotherapy 71:4, pages 1031-1036.
Crossref
Crossref
Narasimha M. Midde, Mohammad A. Rahman, Chetan Rathi, Junhao Li, Bernd Meibohm, Weihua Li & Santosh Kumar. (2016) Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method. PLOS ONE 11:2, pages e0149225.
Crossref
Crossref
Takashi Masaoka, Haiyan Zhao, Danielle R. Hirsch, Michael P. D’Erasmo, Christine Meck, Brittany Varnado, Ankit Gupta, Marvin J. Meyers, Joel Baines, John A. Beutler, Ryan P. Murelli, Liang Tang & Stuart F. J. Le Grice. (2016) Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors. Biochemistry 55:5, pages 809-819.
Crossref
Crossref
Yonghou Jiang, Shijie Cao, Danielle K. Bright, Alaina M. Bever, Anna K. Blakney, Ian T. Suydam & Kim A. Woodrow. (2015) Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell–Cell HIV Transmission. Molecular Pharmaceutics 12:12, pages 4363-4374.
Crossref
Crossref
Thibault Mesplède & Mark Wainberg. (2015) Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses 7:7, pages 3703-3718.
Crossref
Crossref